NUVL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuvalent, Inc. (NUVL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including upcoming FDA approvals, favorable analyst ratings, and bullish technical indicators. Despite the lack of immediate trading signals and modest financial performance, the long-term growth potential outweighs short-term risks.
The stock shows bullish momentum with MACD above 0 and positively contracting, RSI in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 105.835 and 108.505, with support at 97.195 and 94.525. Current pre-market price is 105.1, near resistance levels, indicating upward momentum.
Submission of NDA to the FDA for neladalkib, with breakthrough therapy designation.
Positive clinical trial results for ALK-positive NSCLC treatment.
Analyst ratings are consistently bullish, with price targets ranging from $116 to $
Upcoming FDA approvals within 12-18 months.
No immediate trading signals from AI Stock Picker or SwingMax.
Financials show no revenue and a net loss, though losses are narrowing YoY.
In Q4 2025, the company reported no revenue growth and a net loss of $118.7M, though net income improved by 58.78% YoY. EPS increased by 50.48% YoY, showing progress in reducing losses.
Analysts are bullish on Nuvalent, with multiple firms initiating or maintaining Buy/Overweight ratings. Price targets have been raised recently, with the highest at $140, reflecting confidence in the company's drug pipeline and potential FDA approvals.
